Close
Nordic 9Nordic 9

CGS Holding AS (investor - Corporate Investor)

Sweden
See something wrong or missing? Let us know
Offices:Trelleborg, Prague

CGS Holding a.s. is part of the holding company Sundt, together with Helene Sundt AS and manufactures automotive automobile tires for offroad and agricultural use.

The company was incorporated in 2011 and is based in Prague, Czech Republic. As of May 31, 2016, CGS Holding a.s. operates as a subsidiary of Trelleborg AB, which bought it for approximately SEK 10.9 billion on a cash and debt-free basis. CGS is headquartered in the Czech Republic and generated sales of approximately SEK 5.6 billion in 2015 with an operating margin of 16.5 percent.

Average round investment:14.55M USD
Average number per year:1.0
Distribution: 2020 (1)2017 (1)
Portfolio companies: Norway Oncoinvent
Mostly invests in: Norway Norway (2) Biotech (2)

2 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to CGS Holding AS

Name Criteria
Norway Helene Sundt AS
70%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Norway
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom Advent Life Sciences
66%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Agilent Technologies
66%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
France Alter Equity
66%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Italy AurorA Science
66%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Biospring Partners
66%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Switzerland Essential Investments
66%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Switzerland Jaquet Partners
66%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom Longwall Ventures
66%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Recipharm Venture Fund
66%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top